Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.070
0.00 (0.00%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Cardiol Therapeutics Cash Flow Statement

Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Net Income
-36.68-28.13-30.93-31.64-20.64
Upgrade
Depreciation & Amortization
0.230.250.220.220.23
Upgrade
Asset Writedown & Restructuring Costs
0.15-1.360.080.08
Upgrade
Stock-Based Compensation
14.284.175.5412.612.81
Upgrade
Other Operating Activities
-2.1-0.93-9.15-4.890.07
Upgrade
Change in Accounts Receivable
0.040.07-0.14-0.060.01
Upgrade
Change in Inventory
---0.025.85
Upgrade
Change in Accounts Payable
-1.06-1.294.472.391.83
Upgrade
Change in Other Net Operating Assets
0.090.681.42-2.270.64
Upgrade
Operating Cash Flow
-25.06-25.18-27.22-23.54-9.13
Upgrade
Capital Expenditures
-0.02-0.06-0.07-0.01-0.04
Upgrade
Investing Cash Flow
-0.02-0.06-0.07-0.01-0.04
Upgrade
Long-Term Debt Repaid
-0.04-0.06-0.05-0.05-0.05
Upgrade
Net Debt Issued (Repaid)
-0.04-0.06-0.05-0.05-0.05
Upgrade
Issuance of Common Stock
21.53--98.7217.43
Upgrade
Other Financing Activities
-2.65---5.23-1.09
Upgrade
Financing Cash Flow
18.84-0.06-0.0593.4416.3
Upgrade
Foreign Exchange Rate Adjustments
1.890.762.92-0.01-0.06
Upgrade
Net Cash Flow
-4.35-24.54-24.4369.877.07
Upgrade
Free Cash Flow
-25.08-25.24-27.3-23.55-9.17
Upgrade
Free Cash Flow Margin
----29904.22%-
Upgrade
Free Cash Flow Per Share
-0.35-0.39-0.44-0.55-0.31
Upgrade
Levered Free Cash Flow
-11.86-14.99-20.64-4.61-1.61
Upgrade
Unlevered Free Cash Flow
-11.86-14.99-20.64-4.61-1.61
Upgrade
Change in Net Working Capital
1.170.730.49-6.74-8.32
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q